NEW METHODS WILL BE DEVELOPED TO MEASURE THE ACTIVITY OF TUMOR METABOLIC PATHWAYS IN PATIENTS WITH GLIOBLASTOMA AND TO DETERMINE WHETHER DRUGS DESIGNED TO BLOCK THESE PATHWAYS ARE SUITABLE.